Webinar: A new imaging technology to visualize, analyze, and spatially map key biomarkers

Multiplexed immunofluorescent imaging sheds new light on cancer and other complex conditions. This imaging technique offers a deeper understanding of cells and their surroundings by providing a detailed view of disease biology, including different cell types, biomarker expression, and immune response. The ability to both quantify and spatially analyze cellular biomarkers in tissue, coupled with the opportunity to decipher cellular mechanisms for innovative targeted treatment strategies, has the potential to make cancer therapeutics more targeted and effective than before.

In this webinar, we will discuss how collaborative efforts and a focus on the critical needs of patients, researchers, and industry led to the development of Cell DIVE™ multiplexed immunofluorescence imaging. We incorporated existing, proven technologies and customer feedback to validate and continuously improve this novel imaging solution, providing new knowledge to all involved and advancing immuno-oncology in the process.

Learning Objectives:
• Explore the complexity of the tumor microenvironment (histology, cell types, and proteins)
• Outline approaches for spatial cell analysis
• Reinforce the importance of reproducibility in multiplexed imaging, including antibody validation, controls, and calibration
• Gain tips to develop a robust, reliable multiplexed imaging applications
1) Identification of customer needs and wants
2) Incorporation of teamwork and continuous improvement through the sharing of data with both external collaborators and internal stakeholders
3) Discuss product benefits and review how multiplexed imaging technology enables cancer researchers

Speakers:

Paul Goodwin
Science Director, Cytiva
President, The Histochemical Society
Paul Goodwin is Science Director for Cytiva, formerly GE Healthcare Life Sciences, and resides in Seattle, WA. He studied biology at the University of California, San Diego and physiology and biophysics at the University of Washington, Seattle. He created and managed the Image Analysis Laboratory at the Fred Hutchinson Cancer Research Center in Seattle prior to joining Applied Precision, where he was effectively the Chief Scientific Officer (CSO) prior to its acquisition by GE Healthcare. He is the inventor of thirteen patents and has authored numerous peer-reviewed scientific papers and book chapters. He regularly teaches at the Marine Biological Laboratory in Woods Hole, MA, is the Co-Director of Immunohistochemistry and Microscopy at Montgomery College in Germantown, MD, and is the President of the Histochemical Society. He serves on a number of advisory councils and is a member of the Leadership Advisory Council for the Advanced Regenerative Manufacturing Institute.

Fiona Ginty
Technology Manager for Biosciences
General Electric Research Center
Fiona Ginty is a Technology Manager for Biosciences at General Electric's Research Center in Niskayuna, Upstate New York. For over a decade, she has led a multidisciplinary team that developed the Cell DIVE multiplexed immunofluorescence imaging technology. As part of their foundational research into multiplexing lab protocols, imaging hardware, and analysis software, the team collaborated with researchers across the US and globally to better understand their tissue imaging and biomarker needs. They then translated that back to Cell DIVE. To date, the team has published over 30 peer-reviewed articles on the technology and oncology applications. Prior to GE Research, Fiona was a senior scientist for the UK Medical Research Council, Cambridge UK and a post-doctoral scientist at Nestlé Research Center, Lausanne, Switzerland.

Prachi Bogetto
Diagnostics Segment Leader/Marketing Leader Cell Analysis
Cytiva
Prachi Bogetto is responsible for product management and marketing within the Cellular Analysis business at Cytiva. She is a scientist by education, with degrees in biochemistry and molecular biology. Her career as a bench scientist was spent working on gene therapy when it was an idea only the most intrepid were investing in and she is thrilled to see some true patient benefit in recent years. She is especially optimistic about the promise of immunotherapies, including CAR-T therapies, to move cancer treatment forward.